2020年8月27~29日,第55届欧洲肝脏研究学会年会(EASL2020)暨国际肝脏会议(TheDigitalInternationalLiverCongress™2020,ILC2020)将在欧洲最大的城市——英国·伦敦盛大召开。  

既往欧洲国际肝病大会现场都会汇集来自世界各地的专家,借此了解肝脏研究的最新进展。与以往不同的是,鉴于COVID-19大流行的影响,今年大会完全改为线上举行。  

EASL2020:最新肝病领域「重磅研究」概览!

今年大会共收集了来自55个国家专家学者的研究摘要,其中1470+多篇原创研究成果将在壁报和视频展示。依照惯例,今年筛选出8项最新突破研究和13项重磅研究分别在最新突破专题(LateBreaker)和全体大会(Generalsession)由团队代表进行口头报告。重磅研究见下:  

GS01苯扎贝特(Bezafibrate)联合治疗可提高原发性胆管炎无肝移植患者的存活率:一项日本全国性队列研究  

GS01Bezafibrateadd-ontherapyimproveslivertransplantation-freesurvivalinpatientswithprimarybiliarycholangitis:aJapanesenationwidecohortstudy  

AtsushiTanaka,JapanCo-author:ChristopheCorpechot  

27August202013:15-13:30  

GS02粪便亚基因组中的毒性相关基因与酒精性肝炎患者死亡率相关  

GS02Virulence-relatedgenesinfaecalmetagenomesassociatedwithmortalityinpatientswithalcoholichepatitis  

SonjaLang,UnitedStatesCo-author:BerndSchnabl  

27August202013:30-13:45  

GS03端粒相关基因突变患者的肝脏受累:患病率、临床、影像学、病理学特征、转归和危险因素  

GS03Liverinvolvementinpatientswithtelomere-relatedgenesmutations:prevalence,clinical,radiological,pathologicalfeatures,outcomeandriskfactors  

SabrinaSIDALI,FranceCo-author:AuréliePlessier  

27August202013:45-14:00  

GS04肠道微生物群通过促进TLR4依赖的单核细胞髓源性抑制细胞的增殖来促进肝癌发生  

GS04GutmicrobiotadriveshepatocarcinogenesisbypromotingTLR4-dependentexpansionofmonocyticmyeloid-derivedsuppressorcells  

KaiMarkusSchneider,GermanyCo-author:AntjeMohs  

27August202014:00-14:15  

GS05欧洲国家器官储运组织终末期肝病钠评分的模型验证  

GS05ValidationoftheModelforEnd-stageLiverDiseasesodiumscorefortheEurotransplantregion.  

BenGoudsmit,NetherlandsCo-author:BartVanHoek  

27August202014:15-14:30  

GS06一项随机、多中心、双盲、安慰剂对照试验:左旋肉碱对肝硬化患者和隐性肝性脑病患者生活质量的影响  

GS06Arandomised,multi-centre,double-blinded,placebocontrolled,investigator-initiatedtrialtoassesstheimpactofL-carnitineadministrationonqualityoflifeincirrhosispatientsandcoverthepaticencephalopathy  

EileenYoon,Korea,Rep.ofSouth  

27August202014:30-14:45  

GS07Nidufexor,一种非胆汁酸FXR激动剂,在给药12周后降低NASH患者的ALT水平和肝脂肪分数  

GS07Nidufexor,anon-bileacidFXRagonist,decreasesALTandhepaticfatfractioninpatientswithNASHafter12weeksdosing  

RichardAspinall,UnitedKingdomCo-author:MichaelBadman  

27August202014:45-15:00  

GS08在初级保健中引入"reflex"AST检测可提高晚期肝病的检出率:TheGwentASTProject(GAP)  

GS08Introductionof"reflex"ASTtestinginprimarycareincreasesdetectionofadvancedliverdisease:TheGwentASTProject(GAP)  

AndrewYeoman,UnitedKingdomCo-author:Dr.FidanYousuf  

28August202013:30-13:45  

GS09单酰甘油脂肪酶重组巨噬细胞和肝细胞的脂质代谢,促进肝再生  

GS09Monoacylglycerollipasereprogrammeslipidmetabolisminmacrophagesandhepatocytestopromoteliverregeneration  

ManonAllaire,FranceCo-author:HélèneGilgenkrantz  

28August202013:45-14:00  

GS10在接受核苷类似物治疗的慢性乙型肝炎患者中,用RNA干扰疗法(JNJ-3989)进行短期治疗可持续抑制乙型肝炎表面抗原  

GS10Short-termtreatmentwithRNAinterferencetherapy,JNJ-3989,resultsinsustainedhepatitisBsurfaceantigensuppressioninpatientswithchronichepatitisBreceivingnucleos(t)ideanaloguetreatment  

EdwardGane,NewZealandCo-author:StephenLocarnini  

28August202014:00-14:15  

GS11巨噬细胞清道夫受体1介导肥胖相关非酒精性脂肪肝的脂质性炎症反应  

GS11MacrophageScavengerReceptor1mediateslipid-inducedinflammationinhumanobesity-relatednon-alcoholicfattyliverdisease  

OlivierGovaere,UnitedKingdomCo-author:QuentinAnstee  

28August202014:15-14:30  

GS12自身免疫性肝炎肝移植术后患者和移植物的长期存活率  

GS12Long-termpatientandgraftsurvivalafterlivertransplantationforautoimmunehepatitis  

MelinaHeinemann,GermanyCo-author:ChristophSchramm  

28August202014:30-14:45  

GS13HCV消除后肝硬化患者血清常规参数和AFP演变的分析,用于HCC风险分层:来自ANRSCO12CirVir队列的轨迹聚群分析  

GS13ProfilingofRoutineserumparametersandAFPevolutionincirrhosisfollowingHCVeradicationforstratificationofHCCrisk:atrajectoryclusteringanalysisfromtheANRSCO12CirVircohort  

PierreNahon,FranceCo-author:EtienneAudureau  

28August202014:45-15:00  

信源:ESAL官网


声明:
不要轻信任何医疗广告或新闻报道式广告!
请勿轻信素未谋面的网络医生!
本站所刊载的信息仅供参考,不能代表医生的诊断和治疗,请勿直接对照治疗而延误病情!
因个人主职工作时间不宽裕,网站未来仅保持不定期更新。